文献速递胸部肿瘤放疗放疗物理与技术

患者报告结局与剂量学指标用于早期识别急性放疗相关食管炎

Patient-Reported Outcome Measures and Dosimetric Correlates for Early Detection of Acute Radiation Therapy-Related Esophagitis.
PubMed 文献 · Pract Radiat Oncol · 2020-10-31

本研究纳入200例接受常规分割放疗的肺癌患者,每周采用PRO-CTCAE评估吞咽困难,并分析食管V60与症状的关系。结果显示38%患者报告≥中度吞咽困难,仅13%被医生评为CTCAE 2级及以上吞咽困难;患者报告症状出现更早、更频繁,食管V60>7%与患者报告≥中度食管症状最相关(OR 6.1)。

要点

  • 患者报告≥中度吞咽困难的发生率(38%)远高于医生评估的CTCAE 2+级(13%)。
  • 患者报告症状中位出现时间21天,早于医生报告的33天。
  • 食管V60>7%与患者报告≥中度吞咽困难最相关(OR 6.1,95%CI 3.0-12.3)。

核心结论

  • 患者报告的≥中度吞咽困难比医生报告的CTCAE 2+级吞咽困难更常见且出现更早。
  • 食管V60>7%与患者报告≥中度食管症状的开发最相关。

研究设计与样本

  • 每周采用PRO-CTCAE v.1评估吞咽困难,医生采用CTCAE v.4评估吞咽困难。
  • 排除放疗开始7天内报告≥中度症状的患者,最终纳入200例。

主要发现

  • 200例患者中位年龄69岁,52%男性,89%为III+期,中位放疗剂量63 Gy,91.5%接受化疗。
  • 76/200(38%)报告≥中度吞咽困难,26/200(13%)被医生评为CTCAE 2+级吞咽困难。
  • 患者报告症状中位时间21天(IQR 18-34.5),医生报告中位时间33天(IQR 24-42)。
  • 30天患者报告≥中度吞咽困难累积发生率为26%(95%CI 20%-32%),医生报告CTCAE 2+级为6%(95%CI 3%-9%)。
  • 食管V60>7%与患者报告≥中度食管症状的OR为6.1(95%CI 3.0-12.3)。

关键数值与推荐

  • PRO-CTCAE v.1吞咽困难评分:0无,1轻度,2中度,3重度,4极重度。
  • CTCAE v.4吞咽困难分级:0无,1症状不影响进食,2有症状需改变进食/吞咽,3严重改变进食/吞咽,4危及生命,5死亡。
  • 食管V60>7%被确定为与患者报告≥中度食管症状最相关的临床因素。

临床怎么用

  • 在肺癌放疗中应常规采用患者报告结局(如PRO-CTCAE)动态监测吞咽困难,以更早发现症状。
  • 计划设计时关注食管V60,将其控制在≤7%可能降低患者报告≥中度吞咽困难的风险。

局限性

  • 基线肿瘤相关吞咽困难未记录,可能影响症状归因。
  • 单中心回顾性设计,结果外推需谨慎。
  • 样本仅限肺癌患者,其他瘤种需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We investigate the time to and clinical factors associated with patient-reported difficulty swallowing in lung cancer patients treated with radiation therapy (RT). METHODS: Between October 2016 and October 2019, lung cancer patients treated with conventionally fractionated RT at a tertiary cancer center were identified. Weekly, patients reported difficulty swallowing (patient-reported outcome version of the Common Terminology Criteria for Adverse Events [PRO-CTCAE] v.1: 0-none, 1-mild, 2-moderate, 3-severe, 4-very severe). Physicians graded dysphagia (CTCAE v.4: 0-none, 1-symptoms without altered intake, 2-symptomatic; altered eating/swallowing, 3-severely altered eating/swallowing, 4-life-threatening consequences, 5-death). Tumor-related difficulty swallowing was not recorded at baseline; thus, patients reporting ≥moderate symptoms ≤7 days of RT start were excluded. We evaluated the time to new patient reports of ≥moderate difficulty swallowing and CTCAE grade 2+ dysphagia and development over time using the cumulative incidence method. Multivariable logistic regression evaluated associations between clinical factors, esophageal V60, and development of esophageal symptoms. RESULTS: Of the 200 patients identified: median age was 69 years, 52% were male, and 89% had stage III+ disease. Patients received a median of 63 Gy with chemotherapy (91.5%). At least moderate difficulty swallowing during RT was reported by 76 of 200 patients (38%); clinicians rated dysphagia as altering oral intake or worse for 26 of 200 (13%). Median time to first report of symptoms was 21 days (interquartile ratio [IQR], 18-34.5) for the 76 patients who reported ≥moderate symptoms and 33 days (IQR, 24-42) in the 26 patients whose provider reported grade 2+ dysphagia. The 30-day incidence of patient-reported ≥moderate swallowing difficulty and provider grade 2+ dysphagia was 26% (95% CI: 20%-32%) and 6% (95% CI: 3%-9%), respectively. Esophageal V60 >7 % was the clinical factor most associated with patient-reported ≥moderate esophageal symptoms (odds ratio 6.1, 95% CI: 3.0-12.3). CONCLUSIONS: Patients report at least moderate difficulty swallowing more often and earlier than providers report grade 2+ dysphagia. Esophageal V60 ≥7% was most associated with development of moderate severity or worse patient-reported swallowing difficulty.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Voong KR, Han P, Hales R, et al. Patient-Reported Outcome Measures and Dosimetric Correlates for Early Detection of Acute Radiation Therapy-Related Esophagitis. Pract Radiat Oncol. 2020. PMID: 33137465. doi:10.1016/j.prro.2020.10.009

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。